Sapient provides multiomic biomarker discovery services based on high throughput mass spectrometry, bioinformatics, and access to a longitudinal human biology dataset. Sapient’s insights into dynamic biomarkers enable biopharma to make better decisions when prioritizing targets, patient populations, and drugs during discovery, development, clinical trials, or even following failed trials.
Dr. Usuka will lead global business strategy for commercial collaborations, strategic partnerships & client service innovations.
These services enable measure of thousands of proteins in blood and tissue across diverse biological pathways.
These ready-to-order panels speed time-to-insight through targeted exploration of known molecules.
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis, announced that its high complexity CLIA laboratory has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, Sapient passed a rigorous evaluation process that involved an in-depth inspection of its clinical… Continue reading Sapient’s High Complexity CLIA Laboratory Receives Accreditation from the College of American Pathologists (CAP)
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics with data analysis and chemical interpretation for the study. The research is part… Continue reading University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating that 56% of adults in the study… Continue reading Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
© Care Equity Capital Management L.P. New York, New York
